Ayuda
Ir al contenido

Dialnet


Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

  • Autores: Erika Vacchelli, Yuting Ma, Antonella Sistigu, Federico Pietrocola
  • Localización: Science, ISSN 0036-8075, Vol. 350, Nº 6263, 2015, págs. 973-978
  • Idioma: inglés
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1−/− mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno